Euroholdings Ltd Reports Results for the Quarter and Six-Month Period, Ended June 30, 2025 and Announces Decision to Focus on the Tanker Sector

Euroholdings Ltd. (EHLD) furnished an SEC Form 6-K — earnings release. INFORMATION CONTAINED IN THIS FORM 6-K REPORT Attached to this report on Form 6-K as Exhibit 1 is a copy of the press release issued by Euroholdings Ltd on August 12, 2026 entitled: EuroHoldings Ltd Reports Results for the Quarter and Six-Month Period, Ended June 30, 2026. SIGNAT

Meta Platforms' AI infrastructure spending is causing financial strain. Free cash flow turned negative in Q3 2026, and future commitments reached $825 billion. This reflects rising pressure on the company's financing power, according to Bloomberg.

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.

Climb Bio (CLYM) reported early Phase 2 data for budoprutug in pMN, showing B-cell depletion, antibody reduction, and immunologic remission at 12 weeks. Both 200 mg and 600 mg doses were generally well tolerated. The company expects further data in 2027.

Climb Bio (CLYM) presented Phase 2 data for budoprutug, its anti-CD19 mAb, at ASN Kidney Week. The 200 mg dose showed B-cell depletion, PLA2R Ab reduction, and immunologic remission in pMN patients. A separate case study reported 3-year steroid-free remission in an MCD patient. Additional data is expected in 2027. The drug was generally well-tolerated.

Amgen's Phase III trial showed that IMDELLTRA plus IMFINZI reduced death risk by 58% vs. IMFINZI alone in extensive-stage small-cell lung cancer, with a hazard ratio of 0.42. The combo also improved progression-free survival and response rates. Amgen plans global regulatory submissions and further studies. According to the company, adverse events were manageable.